{"disease":{"id":"neuroendocrine-tumor-grade-1","name":"neuroendocrine tumor grade 1"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03375320","title":"Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":298,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06981455","title":"Life Following Excision of Neuroendocrine Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":246,"lead_sponsor_name":"Sunnybrook Health Sciences Centre","has_results":false},{"nct_id":"NCT07185672","title":"PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":162,"lead_sponsor_name":"Tata Memorial Hospital","has_results":false},{"nct_id":"NCT06395402","title":"177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"University of Iowa","has_results":false},{"nct_id":"NCT06472388","title":"Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"AC Camargo Cancer Center","has_results":false},{"nct_id":"NCT04464122","title":"Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"University of Roma La Sapienza","has_results":false},{"nct_id":"NCT06855095","title":"Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":39,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT06148636","title":"A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"David Bushnell","has_results":false},{"nct_id":"NCT05111509","title":"A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Yusuf Menda","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}